Literature DB >> 6129243

Cross-linking of alpha 2-plasmin inhibitor to fibrin catalyzed by activated fibrin-stabilizing factor.

T Tamaki, N Aoki.   

Abstract

During blood coagulation alpha 2-plasmin inhibitor (alpha 2PI) is cross-linked with fibrin by an activated fibrin-stabilizing factor (FSFa) plasma transglutaminase, activated coagulation factor XIII). When alpha 2PI was treated with FSFa in the absence of acceptor amino groups, the inhibitor lost more than 90% of its capacity to be cross-linked to fibrin because of hydrolysis of the gamma-carboxamides of FSFa-susceptible glutamine residues. Chemical modifications of the inhibitor's lysine epsilon-amino groups did not affect the cross-linking capacity of the inhibitor with fibrin, whereas the same chemical modifications in fibrinogen resulted in a remarkable loss of cross-linking capacity. These observations suggest that alpha 2PI plays a role as an acyl donor with its FSFa-susceptible glutamine residues in the cross-linking reaction with fibrin, and fibrin serves as an acyl acceptor with its lysine residues. The number of FSFa-susceptible glutamine residues/molecule of the inhibitor was estimated by measuring the maximum incorporation of [3H]histamine into the inhibitor and by analyzing the distribution of radioactivity in a tryptic digest of [14C]histamine-incorporated alpha 2PI.l It was found that each inhibitor molecule has one glutamine residue that is most susceptible to FSFa. When the radioactive histamine-incorporated inhibitor was reacted with excess amounts of plasmin, a small fragment carrying all the released radioactivity was rapidly released from the NH2-terminal part of the inhibitor moiety of the complex. The NH2-terminal amino acid sequence of the inhibitor was analyzed before and after treatment with FSFa or before and after incorporation of radioactive histamine. The glutamine residue at the second position from the NH2-terminal end was converted to a glutamic acid residue when the inhibitor was treated with FSFa. When the radioactive histamine-incorporated inhibitor ws analyzed, the radioactivity was found predominantly at the second position from the NH2-terminal end. These results indicate that the glutamine residue susceptible to FSFa in alpha 2PI is located next to the NH2-terminal residue.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6129243

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

1.  Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking.

Authors:  J D Beckman; L A Holle; A S Wolberg
Journal:  J Thromb Haemost       Date:  2017-11-20       Impact factor: 5.824

2.  Stopped-flow fluorescence kinetics of bovine alpha 2-antiplasmin inhibition of bovine midiplasmin.

Authors:  S Christensen; L Sottrup-Jensen; U Christensen
Journal:  Biochem J       Date:  1995-01-01       Impact factor: 3.857

3.  alpha 2-Antiplasmin Enschede: dysfunctional alpha 2-antiplasmin molecule associated with an autosomal recessive hemorrhagic disorder.

Authors:  C Kluft; H K Nieuwenhuis; D C Rijken; E Groeneveld; G Wijngaards; W van Berkel; G Dooijewaard; J J Sixma
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

4.  Organization of the human alpha 2-plasmin inhibitor gene.

Authors:  S Hirosawa; Y Nakamura; O Miura; Y Sumi; N Aoki
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

Review 5.  Transglutaminases.

Authors:  L Lorand; S M Conrad
Journal:  Mol Cell Biochem       Date:  1984       Impact factor: 3.396

6.  Alpha 2-antiplasmin supplementation inhibits tissue plasminogen activator-induced fibrinogenolysis and bleeding with little effect on thrombolysis.

Authors:  J I Weitz; B Leslie; J Hirsh; P Klement
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

7.  Evidence that alpha2-antiplasmin becomes covalently ligated to plasma fibrinogen in the circulation: a new role for plasma factor XIII in fibrinolysis regulation.

Authors:  M W Mosesson; K R Siebenlist; I Hernandez; K N Lee; V J Christiansen; P A McKee
Journal:  J Thromb Haemost       Date:  2008-06-16       Impact factor: 5.824

8.  Aspirin inhibits vascular plasminogen activator activity in vivo. Studies utilizing a new assay to quantify plasminogen activator activity.

Authors:  R I Levin; P C Harpel; D Weil; T S Chang; D B Rifkin
Journal:  J Clin Invest       Date:  1984-08       Impact factor: 14.808

9.  Exogenous fibrin matrix precursors stimulate the temporal progress of nerve regeneration within a silicone chamber.

Authors:  L R Williams
Journal:  Neurochem Res       Date:  1987-10       Impact factor: 3.996

10.  Release of alpha 2-plasmin inhibitor from plasma fibrin clots by activated coagulation factor XIII. Its effect on fibrinolysis.

Authors:  J Mimuro; S Kimura; N Aoki
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.